METOCLOPRAMIDE HCL
ANTIEMETIC · GASTROESOPHAGEAL REFLUX DISEASE ·+1
LEHIGH VALLEY T
Drug class
GI Stimulants
Gastrointestinal stimulants, widely referred to in clinical practice as prokinetic agents, are a therapeutic drug class that enhances gastrointestinal smooth muscle motility and accelerates luminal transit without functioning primarily as purgative laxatives. Read more about GI Stimulants
40 drugs in this class 38 manufacturers
Drugs in GI Stimulants
METOCLOPRAMIDE HCL
ANTIEMETIC · GASTROINTESTINAL RADIOGRAPHY ADJUNCT ·+4
AVENACY, INC
METOCLOPRAMIDE HCL
ANTIEMETIC · GASTROESOPHAGEAL REFLUX DISEASE ·+1
UNICHEM-IPCA
METOCLOPRAMIDE HCL
ANTIEMETIC · GASTROINTESTINAL RADIOGRAPHY ADJUNCT ·+4
Avet Pharmaceuticals
METOCLOPRAMIDE HCL
ANTIEMETIC · GASTROINTESTINAL RADIOGRAPHY ADJUNCT ·+4
Hospira
METOCLOPRAMIDE HCL
ANTIEMETIC · GASTROESOPHAGEAL REFLUX DISEASE ·+1
SCIEGEN PHARMAC
PRUCALOPRIDE (prucalopride succinate)
GI STIMULANTS · CHRONIC IDIOPATHIC CONSTIPATION
CAMBER PHARMACE
PRUCALOPRIDE (prucalopride succinate)
GI STIMULANTS · CHRONIC IDIOPATHIC CONSTIPATION
APOTEX CORP
PRUCALOPRIDE (prucalopride succinate)
GI STIMULANTS · CHRONIC IDIOPATHIC CONSTIPATION
LUPIN PHARMACEU
Filter & compare in the drug finder →
Opens the drug finder with GI Stimulants preselected. Add indication or manufacturer filters there.
Gastrointestinal stimulants, widely referred to in clinical practice as prokinetic agents, are a therapeutic drug class that enhances gastrointestinal smooth muscle motility and accelerates luminal transit without functioning primarily as purgative laxatives.
These medications typically act by modulating enteric neurotransmission—most commonly through dopamine-2 receptor antagonism, serotonin receptor modulation (such as 5-HT4 receptor agonism), or direct cholinergic stimulation—to augment coordinated contractions, increase lower esophageal sphincter tone, and accelerate gastric emptying.
Clinically, GI stimulants are predominantly indicated for motility-related upper gastrointestinal conditions, including diabetic and idiopathic gastroparesis, refractory gastroesophageal reflux disease (GERD), and select functional dyspepsia syndromes.
-
nih.gov
Gastrointestinal stimulants, widely referred to in clinical practice as prokinetic agents, are a therapeutic drug class that enhances gastrointestinal smooth muscle motility and accelerates luminal transit without functioning primarily as purgative laxatives
-
nih.gov
Gastrointestinal stimulants, widely referred to in clinical practice as prokinetic agents, are a therapeutic drug class that enhances gastrointestinal smooth muscle motility and accelerates luminal transit without functioning primarily as purgative laxatives
-
drugs.com
Gastrointestinal stimulants, widely referred to in clinical practice as prokinetic agents, are a therapeutic drug class that enhances gastrointestinal smooth muscle motility and accelerates luminal transit without functioning primarily as purgative laxatives Clinically, GI stimulants are predominantly indicated for motility-related upper gastrointestinal conditions, including diabetic and idiopathic gastroparesis, refractory gastroesophageal reflux disease (GERD), and select functional dyspepsia...
-
nih.gov
These medications typically act by modulating enteric neurotransmission—most commonly through dopamine-2 receptor antagonism, serotonin receptor modulation (such as 5-HT₄ receptor agonism), or direct cholinergic stimulation—to augment coordinated contractions, increase lower esophageal sphincter tone, and accelerate gastric emptying
-
pharmacytimes.com
These medications typically act by modulating enteric neurotransmission—most commonly through dopamine-2 receptor antagonism, serotonin receptor modulation (such as 5-HT₄ receptor agonism), or direct cholinergic stimulation—to augment coordinated contractions, increase lower esophageal sphincter tone, and accelerate gastric emptying
-
truemeds.in
These medications typically act by modulating enteric neurotransmission—most commonly through dopamine-2 receptor antagonism, serotonin receptor modulation (such as 5-HT₄ receptor agonism), or direct cholinergic stimulation—to augment coordinated contractions, increase lower esophageal sphincter tone, and accelerate gastric emptying Clinically, GI stimulants are predominantly indicated for motility-related upper gastrointestinal conditions, including diabetic and idiopathic gastroparesis, refrac...
-
aacnjournals.org
These medications typically act by modulating enteric neurotransmission—most commonly through dopamine-2 receptor antagonism, serotonin receptor modulation (such as 5-HT₄ receptor agonism), or direct cholinergic stimulation—to augment coordinated contractions, increase lower esophageal sphincter tone, and accelerate gastric emptying
-
drugs.com
Clinically, GI stimulants are predominantly indicated for motility-related upper gastrointestinal conditions, including diabetic and idiopathic gastroparesis, refractory gastroesophageal reflux disease (GERD), and select functional dyspepsia syndromes
-
nih.gov
Clinically, GI stimulants are predominantly indicated for motility-related upper gastrointestinal conditions, including diabetic and idiopathic gastroparesis, refractory gastroesophageal reflux disease (GERD), and select functional dyspepsia syndromes
Sign in to follow this class
Following a drug class requires a free Physicians Office Resource account.